W. Li
Impact in
- Oncology top 5%
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 29
- HER2/EGFR in Cancer Research 9
- Lung Cancer Research Studies 8
- Colorectal Cancer Treatments and Studies 7
- PARP inhibition in cancer therapy 5
- Cancer Immunotherapy and Biomarkers 5
- Cancer Treatment and Pharmacology 5
-
- Lung Cancer Treatments and Mutations 13
- Advanced Breast Cancer Therapies 9
- Co-authors
- Binghe XuCarsten GoesslElżbieta SenkusPierfranco ContéSusan M. DomchekAnne ArmstrongSeock‐Ah ImMark E. Robson
- Journals
- Annals of Oncology (24 papers)Journal of Thoracic Oncology (4 papers)Clinical & Translational Oncology (1 paper)International Journal of Food Microbiology (1 paper)Blood Advances (1 paper)
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
W. Li
41 papers receiving 965 citations
Hit Papers
Peers
Comparison fields: 5 of 61
- Oncology 684
- Cancer Research 191
- Pulmonary and Respiratory Medicine 337
- Pathology and Forensic Medicine 159
- Genetics 62
Countries citing papers authored by W. Li
This map shows the geographic impact of W. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Li more than expected).
Fields of papers citing papers by W. Li
This network shows the impact of papers produced by W. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Li. The network helps show where W. Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside W. Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 8 | |
| 5 | 2022 | 2 | |
| 6 | 2022 | 14 | |
| 7 | 2022 | 10 | |
| 8 | 2022 | 3 | |
| 9 | 2020 | 7 | |
| 10 | 2020 | 0 | |
| 11 | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Hit paper breakdown → | 2019 | 497 |
| 12 | 2018 | 4 | |
| 13 | 2018 | 1 | |
| 14 | 2018 | 14 | |
| 15 | 2017 | 10 | |
| 16 | 2017 | 4 | |
| 17 | 2017 | 2 | |
| 18 | 2016 | 2 | |
| 19 | 2015 | 1 | |
| 20 | 2015 | 263 |
About W. Li
W. Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hematology, Hepatology and Otorhinolaryngology, having authored 47 papers that have together received 981 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (9 papers), Lung Cancer Research Studies (8 papers), Colorectal Cancer Treatments and Studies (7 papers), PARP inhibition in cancer therapy (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Oncology (684 citations), Cancer Research (191 citations), Pulmonary and Respiratory Medicine (337 citations), Pathology and Forensic Medicine (159 citations) and Genetics (62 citations). W. Li has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Binghe Xu, Carsten Goessl, Elżbieta Senkus, Pierfranco Conté, Susan M. Domchek, Anne Armstrong, Seock‐Ah Im, Mark E. Robson, Suzette Delaloge and Norikazu Masuda. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Clinical & Translational Oncology, International Journal of Food Microbiology and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.